uniQure « Terug naar discussie overzicht

Analisten over UniQure

243 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 » | Laatste

Omlaag ↓

pim f 18 april 2019 09:21

highlightpress.com/2019/04/17/uniqure...

[verwijderd] 18 april 2019 12:05

quote:
pim f schreef op 18 april 2019 09:21:
highlightpress.com/2019/04/17/uniqure...

1x Sell, 1x Hold en 12x Buy en de kop is "Sell". Highlight Press heeft voor mij afgedaan !

Tex Mex 11 mei 2019 10:21

This Gene Therapy Stock Is Nearing A Breakout On Its Hemophilia B Study

www.investors.com/news/technology/uni...

Tex Mex 16 mei 2019 16:58

Toe maar: Chardan analyst Gbola Amusa raised his price target for uniQure (QURE) to $175 from $100 to reflect the company's opportunity in Huntington's disease.

twitter.com/zbiotech/status/112903186...

pim f 16 mei 2019 23:03

quote:
Tex Mex schreef op 16 mei 2019 16:58:
Chardan analyst Gbola Amusa raised his price target for uniQure (QURE) to $175 from $100 to reflect the company's opportunity in Huntington's disease.

Hoppa, niet van dat benauwde gepriegel

pim f 17 mei 2019 01:00

quote:
Tex Mex schreef op 16 mei 2019 16:58:
Toe maar: Chardan analyst Gbola Amusa raised his price target for uniQure (QURE) to $175 from $100 to reflect the company's opportunity in Huntington's disease.

twitter.com/zbiotech/status/112903186...

Chardan Capital Reiterates a Buy Rating on uniQure NV (QURE)
May 16, 2019

Amusa noted: "We believe uniQure, a 2019, could be en route to $5-10bn valuation, based on support in the coming year from what could be a best-in-class, breakthrough Huntington's disease (HD) franchise. HD is a universally fatal monogenic (autosomal dominant) disease that usually starts between ages 30 and 50, followed by movement, cognitive, and psychiatric impairment. Death typically follows 10 to 30 years after diagnosis. In 2H19, uniQure is expected to make AAV5-based gene therapy (GT), AMT-130, the first 1-time GT to enter the clinic for HD. AMT-130 utilizes uniQure's miQURE silencing technology to inhibit the production of the mutant huntingtin protein (mHTT).

www.markets.co/chardan-capital-reiter...

Prof. Dollar 17 mei 2019 14:28

Video van corporate update uniQure gegeven eind april door Jon Garen, Chief Business Officer. TNX flosz
www.youtube.com/watch?v=WMt2Afh_Wgc

Prof. Dollar 17 mei 2019 20:46

quote:
Prof. Dollar schreef op 17 mei 2019 14:28:
Video van corporate update uniQure gegeven eind april door Jon Garen, Chief Business Officer. TNX flosz
www.youtube.com/watch?v=WMt2Afh_Wgc

Ah, had ik eigenlijk in ander draadje willen plaatsen... het zij zo.

pim f 19 mei 2019 23:25

Brokerages Set Uniqure NV (QURE) Price Target at $75.89

Posted by Brian Wu on May 18th, 2019

Uniqure logoUniqure NV (NASDAQ:QURE) has been assigned an average rating of “Buy” from the fourteen research firms that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $77.22.

Several research analysts have weighed in on QURE shares. Zacks Investment Research upgraded Uniqure from a “sell” rating to a “hold” rating in a research report on Thursday, January 17th. SunTrust Banks increased their price objective on Uniqure to $76.00 and gave the stock a “buy” rating in a research report on Tuesday. BidaskClub upgraded Uniqure from a “sell” rating to a “hold” rating in a research report on Tuesday. Robert W. Baird started coverage on Uniqure in a research report on Thursday, March 28th. They set an “outperform” rating and a $85.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating on shares of Uniqure in a research report on Tuesday, February 26th.

mayfieldrecorder.com/2019/05/18/broke...

colt 31 mei 2019 15:14

30 mei 2019, Volgens InvestorPlace Media:

Als het op biotech-aandelen betref, is uniQure (NASDAQ: QURE ) royalty-royalty's.

Izette 3 juni 2019 16:07

quote:
colt schreef op 31 mei 2019 15:14:
30 mei 2019, Volgens InvestorPlace Media:

Als het op biotech-aandelen betref, is uniQure (NASDAQ: QURE ) royalty-royalty's.

uniQure NV (QURE)

When it comes to biotech stocks, uniQure (NASDAQ:QURE) is gene therapy royalty. That’s because the firm actually created and launched the very first successful gene therapy back in 2012. However, due to the cost of the drug, it was never prescribed. But QURE has turned that successful approval into a platform for further successful development.

This includes the biotech stock’s latest work for hemophilia. QURE has seen great success with its gene therapy program for the blood disorder. After seeing amazing initial results, QURE has moved its top hemophilia medication — AMT-061 — into phase I/IIb trials. This news sent the clinical stage biotech stock up more than 34%. Given its past history of navigating the gene therapy waters to approval, QURE could have another hit on its hand.

Elsewhere, the firm has started trials for the first gene therapy targeting Huntington’s disease and has gene therapies for congestive heart failure in pipelines. All of these are much more “popular” issues and should help QURE actually see prescription growth if successful.

Like most clinical-stage biotech stocks, QURE is a gamble. But it’s a more calculated risk than most given its history and how great its previous results were.

Izette 4 juni 2019 15:54

Dit zegt technisch analist Zacks Investment Research over de stijging van gisteren;

uniQure N.V. QURE was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $57.28 to $63.49 in the past one-month time frame.

The company has seen one negative estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

uniQure currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

flosz 7 juni 2019 18:04

Guggenheim: What Is a Gene Therapy Platform Worth?
twitter.com/biotech_junkie/status/113...

flosz 10 juni 2019 17:43

Barclays
twitter.com/_b_i_o_t_e_c_h_/status/11...

flosz 17 juni 2019 14:11

twitter.com/semodough/status/11405895...

flosz 17 juni 2019 14:32

Suntrust, Leerink
twitter.com/_b_i_o_t_e_c_h_/status/11...
twitter.com/_b_i_o_t_e_c_h_/status/11...

colt 29 oktober 2019 20:22

www.nasdaq.com/events/uniqure-n.v.-ri...

Tex Mex 3 december 2019 12:04

Wow, Goldman Sachs: $98!

$QURE initiated at Buy at Goldman Sachs, PT $98.
Initiated at Outperform at Cowen.

twitter.com/biostocks/status/12018162...

Btw, Chardan voert de lijst nog altijd aan met een koersdoel van $175.

wijzerplaat 3 december 2019 12:55

Tijd voor actie! Alleen is de doos met flappers even op! :-(

[verwijderd] 3 december 2019 13:29

Nasdaq Premarket +17%

243 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 786,89 -54,40 -6,47% 11:23


Germany40^	19.287,50	-6,56%
BEL 20	3.873,75	-5,37%
Europe50^	4.556,22	-6,60%
US30^	36.803,70	-3,96%
Nasd100^	16.636,40	-4,43%
US500^	4.866,88	-4,12%
Japan225^	30.836,50	-4,29%
Gold spot	3.022,99	-0,51%
EUR/USD	1,0970	+0,46%
WTI	59,25	-5,52%